Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
MGX
Metagenomi, Inc. Common Stock
Hemophilia A is a rare disease; MGX's lead program targets rare disease indications through gene editing.
|
$65.31M |
$1.78
+2.30%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$64.13M |
$1.55
-2.52%
|
|
TISI
Team, Inc.
Laboratory Testing & Advisory Services aligns with Team's lab testing and inspection capabilities within its IHT segment.
|
$63.88M |
$14.28
+2.62%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$63.10M |
$19.38
+5.70%
|
|
AAME
Atlantic American Corporation
Bankers Fidelity provides health insurance products (Medicare supplement and group health), expanding L&H offerings.
|
$61.90M |
$2.96
+0.34%
|
|
CDIX
Cardiff Lexington Corporation
Nova Ortho & Spine provides diagnostic and related assessment services, aligning with Diagnostics & Lab Services in Healthcare.
|
$61.01M |
$1.30
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$60.68M |
$13.21
+0.69%
|
|
BLGO
BioLargo, Inc.
Clyra Medical infection control products classify BioLargo under Medical Devices & Biometrics.
|
$59.73M |
$0.19
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$58.98M |
$1.48
+0.68%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$58.96M |
$9.42
+1.18%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
LINK
Interlink Electronics, Inc.
Medical devices & biometrics is a target end-market for Interlink’s sensor and printed electronics solutions.
|
$57.26M |
$3.82
-1.29%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$56.08M |
$12.35
-0.40%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$55.36M |
$9.34
-9.58%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$55.11M |
$0.57
-1.85%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$54.53M |
$4.63
-0.32%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$53.07M |
$2.67
+13.83%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$52.59M |
$4.37
-1.13%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$51.32M |
$2.15
-4.22%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$51.03M |
$3.81
+0.26%
|
|
NEPH
Nephros, Inc.
FDA-cleared medical devices (infection-control filters) used in hospitals and dialysis centers.
|
$50.99M |
$4.84
-3.29%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$49.90M |
$1.07
+7.72%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$49.43M |
$1.57
+2.27%
|
|
AIRG
Airgain, Inc.
AT-Flight asset tracker and its healthcare usage aligns Airgain with Medical Devices & Biometrics as a healthcare-oriented device offering.
|
$47.97M |
$4.00
-1.11%
|
|
NRXS
NeurAxis, Inc.
Core product line: Neuromodulation devices (IB-Stim PENFS).
|
$47.91M |
$4.88
+5.51%
|
|
JANL
Janel Corporation
Life Sciences subsidiaries provide contract manufacturing services (antibody/reagent production, viral vector production).
|
$47.45M |
$40.00
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$46.84M |
$1.13
-5.04%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$46.21M |
$3.90
-3.23%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$45.86M |
$0.00
|
|
LVTX
LAVA Therapeutics N.V.
LAVA Therapeutics operates in oncology biotech, developing cancer therapies based on its Gammabody platform.
|
$45.77M |
$1.65
-5.17%
|
|
XFOR
X4 Pharmaceuticals, Inc.
Company develops therapies targeting rare immune disorders (WHIM syndrome, CN), fitting Biotech - Rare Diseases.
|
$45.63M |
$4.00
-0.87%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$45.40M |
$6.24
-4.00%
|
Showing page 28 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
